Ricevi le ultime notizie sulle azioni Inhibikase Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IKT

Ultime notizie per

INHIBIKASE THERAPEUTICS INC

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP PLC ORD by Intertek Group Plc

Health Care

Press Releases

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Earnings

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

News

Management

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Agenus

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Atossa Therapeutics

Biomea Fusion

Coya Therapeutics

Entera Bio

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Opus Genetics

MDxHealth

Macrogenics

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

Oncolytics Biotech

Ovid Therapeutics

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

Surrozen

Instil Bio

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Inhibikase Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO